RU2756405C2 - Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения - Google Patents

Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения Download PDF

Info

Publication number
RU2756405C2
RU2756405C2 RU2019113370A RU2019113370A RU2756405C2 RU 2756405 C2 RU2756405 C2 RU 2756405C2 RU 2019113370 A RU2019113370 A RU 2019113370A RU 2019113370 A RU2019113370 A RU 2019113370A RU 2756405 C2 RU2756405 C2 RU 2756405C2
Authority
RU
Russia
Prior art keywords
lymphoma
ser
sequence
seq
leu
Prior art date
Application number
RU2019113370A
Other languages
English (en)
Russian (ru)
Other versions
RU2019113370A (ru
RU2019113370A3 (enExample
Inventor
Ян ЭНДЕЛЛЬ
Константин ПЕТРОПУЛОС
Петер Келемен
Райнер БОКСХАММЕР
Маркус РЮКЕРТ
Original Assignee
МорфоСис АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МорфоСис АГ filed Critical МорфоСис АГ
Publication of RU2019113370A publication Critical patent/RU2019113370A/ru
Publication of RU2019113370A3 publication Critical patent/RU2019113370A3/ru
Application granted granted Critical
Publication of RU2756405C2 publication Critical patent/RU2756405C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2019113370A 2016-10-28 2017-10-27 Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения RU2756405C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16196184 2016-10-28
EP16196184.2 2016-10-28
PCT/EP2017/077654 WO2018078123A1 (en) 2016-10-28 2017-10-27 Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof

Publications (3)

Publication Number Publication Date
RU2019113370A RU2019113370A (ru) 2020-11-30
RU2019113370A3 RU2019113370A3 (enExample) 2021-03-01
RU2756405C2 true RU2756405C2 (ru) 2021-09-30

Family

ID=57218739

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019113370A RU2756405C2 (ru) 2016-10-28 2017-10-27 Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения

Country Status (25)

Country Link
US (1) US12358983B2 (enExample)
EP (2) EP3903821A1 (enExample)
JP (3) JP7094950B2 (enExample)
KR (2) KR102500868B1 (enExample)
CN (2) CN109890418B (enExample)
AU (2) AU2017348624B2 (enExample)
BR (1) BR112019008244A2 (enExample)
CA (1) CA3037246A1 (enExample)
CY (1) CY1124648T1 (enExample)
DK (1) DK3532098T3 (enExample)
ES (1) ES2871574T3 (enExample)
HR (1) HRP20210838T1 (enExample)
HU (1) HUE054496T2 (enExample)
IL (3) IL320372A (enExample)
LT (1) LT3532098T (enExample)
MX (2) MX2019004942A (enExample)
PL (1) PL3532098T3 (enExample)
PT (1) PT3532098T (enExample)
RS (1) RS62036B1 (enExample)
RU (1) RU2756405C2 (enExample)
SG (1) SG10202104036QA (enExample)
SI (1) SI3532098T1 (enExample)
SM (1) SMT202100347T1 (enExample)
WO (1) WO2018078123A1 (enExample)
ZA (1) ZA201903302B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
LT3630177T (lt) * 2017-05-31 2023-10-25 Morphosys Ag Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
ES3037206T3 (en) * 2018-08-31 2025-09-30 Adc Therapeutics Sa Combination therapy
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR20220104176A (ko) * 2019-10-31 2022-07-26 모르포시스 아게 순차적 항-cd19 요법
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013024095A1 (en) * 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a purine analog
WO2013024097A1 (en) * 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
WO2015130585A1 (en) * 2014-02-28 2015-09-03 Merck Sharp & Dohme Corp. Method for treating cancer
WO2016130902A1 (en) * 2015-02-12 2016-08-18 Seattle Genetics, Inc. Combination therapy using a cd19-adc and vincristine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
JP2004508420A (ja) 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
ATE552204T1 (de) 2006-08-15 2012-04-15 Hydralift Amclyde Inc Direkt wirkender einzelscheiben-aktiv/passiv- hubkompensator
RU2495882C2 (ru) 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
EP2176298B1 (en) * 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
US20100128586A1 (en) 2008-11-25 2010-05-27 Mediatek Inc. Method and apparatus for accessing data from disc with linking area
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2010263272C1 (en) 2009-06-24 2016-02-11 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
US8549399B2 (en) 2011-01-18 2013-10-01 Apple Inc. Identifying a selection of content in a structured document
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
WO2015082583A1 (en) * 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
AU2015244039B2 (en) * 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
AU2015277516A1 (en) 2014-06-16 2016-12-22 Xencor, Inc. Treatment for chronic lymphocytic leukemia (CLL)
MX392487B (es) 2014-10-20 2025-03-21 Juno Therapeutics Inc Métodos y composiciones para dosificación en terapia celular adoptiva.
PE20180454A1 (es) 2015-05-26 2018-03-05 Hoffmann La Roche Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2
LT3302550T (lt) 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
US10973822B2 (en) 2015-07-02 2021-04-13 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
FI3916392T3 (fi) 2016-05-30 2024-06-03 Incyte Corp Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla
WO2018002031A1 (en) 2016-06-27 2018-01-04 Morphosys Ag Anti-cd19 antibody formulations
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
LT3630177T (lt) 2017-05-31 2023-10-25 Morphosys Ag Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
AU2020267823A1 (en) 2019-05-03 2021-11-11 Incyte Corporation Anti-CD19 therapy in patients having a limited number of NK cells
CN115151565A (zh) 2019-10-31 2022-10-04 莫佛塞斯公司 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法
TW202525340A (zh) 2019-10-31 2025-07-01 美商英塞特公司 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
KR20220104176A (ko) 2019-10-31 2022-07-26 모르포시스 아게 순차적 항-cd19 요법
WO2021259902A1 (en) 2020-06-22 2021-12-30 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint
WO2022117799A2 (en) 2020-12-04 2022-06-09 Morphosys Ag Anti-cd19 combination therapy
CA3255552A1 (en) 2021-12-22 2023-06-29 Incyte Corporation TREATMENT PARADIGM FOR ANTI-CD19 ANTIBODY THERAPY

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013024095A1 (en) * 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a purine analog
WO2013024097A1 (en) * 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
WO2015130585A1 (en) * 2014-02-28 2015-09-03 Merck Sharp & Dohme Corp. Method for treating cancer
WO2016130902A1 (en) * 2015-02-12 2016-08-18 Seattle Genetics, Inc. Combination therapy using a cd19-adc and vincristine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KARLSSON SCH et al. "Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy", 2013, Cancer Gene Therapy, Vol. 20, pp. 386-393. *
САВЧЕНКО В.Г., ПОДДУБНАЯ И.В. и соавт. "Клинические рекомендации по обследованию и лечению больных хроническим лейкозом", II Конгресс гематологов России, 2014, 23 с. [найдено 26.02.2021]. Найдено в Интернете: https://www.blood.ru/documents/clinical%20guidelines/26.%20klinicheskie-rekomendacii-2014-xll.pdf. *

Also Published As

Publication number Publication date
HRP20210838T1 (hr) 2021-08-06
CA3037246A1 (en) 2018-05-03
JP2019533682A (ja) 2019-11-21
PT3532098T (pt) 2021-06-17
CN118045175A (zh) 2024-05-17
JP2024167208A (ja) 2024-12-03
AU2024287178A1 (en) 2025-01-23
US20190241656A1 (en) 2019-08-08
SI3532098T1 (sl) 2021-12-31
KR20190075942A (ko) 2019-07-01
RU2019113370A (ru) 2020-11-30
US12358983B2 (en) 2025-07-15
IL266216B2 (en) 2023-09-01
IL320372A (en) 2025-06-01
AU2017348624B2 (en) 2024-09-26
HUE054496T2 (hu) 2021-09-28
ZA201903302B (en) 2021-04-28
SG10202104036QA (en) 2021-05-28
EP3903821A1 (en) 2021-11-03
EP3532098A1 (en) 2019-09-04
BR112019008244A2 (pt) 2019-07-16
KR20230028571A (ko) 2023-02-28
CN109890418A (zh) 2019-06-14
IL301786A (en) 2023-05-01
IL266216A (en) 2019-06-30
RU2019113370A3 (enExample) 2021-03-01
JP2022137089A (ja) 2022-09-21
LT3532098T (lt) 2021-06-25
MX2022016270A (es) 2023-02-15
SMT202100347T1 (it) 2021-07-12
AU2017348624A1 (en) 2019-03-28
JP7094950B2 (ja) 2022-07-04
CN109890418B (zh) 2024-03-08
EP3532098B1 (en) 2021-04-07
WO2018078123A1 (en) 2018-05-03
KR102500868B1 (ko) 2023-02-16
DK3532098T3 (da) 2021-05-25
ES2871574T3 (es) 2021-10-29
NZ751414A (en) 2025-10-31
CY1124648T1 (el) 2022-07-22
RS62036B1 (sr) 2021-07-30
IL266216B1 (en) 2023-05-01
PL3532098T3 (pl) 2022-01-31
MX2019004942A (es) 2019-08-12
IL301786B2 (en) 2025-09-01
IL301786B1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
RU2756405C2 (ru) Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения
RU2756010C2 (ru) Комбинация антитела к CD19 и ингибитора тирозинкиназы брутона и их применение
US12194095B2 (en) Combinations and uses thereof
CN103732252B (zh) 使用抗cd‑19抗体和氮芥的联合治疗
HK40064491A (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HK40014532A (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HK40014532B (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
NZ793707A (en) Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof